AbbVie's ABBV-1088 trial halted before results
NCT ID NCT06579300
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a Phase 1 study to check the safety and how the body processes ABBV-1088 in healthy adults, including Western, Han-Chinese, and Japanese participants. It also looked at how ABBV-1088 interacts with another drug, itraconazole. The study was terminated early, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ABBV-1088
- What could go wrong
- This trial was terminated early, so no data on safety or effectiveness were collected. It is a very early Phase 1 study in healthy volunteers, not patients, so it cannot show any treatment benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
72 people
The number who actually took part.
- Started
-
Sep 2024
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Body Mass Index (BMI) is \> = 18.0 to \< = 32.0 kg/m\^2 after rounded to the tenths decimal, at Screening and upon confinement. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. * Part 3 Only: Han Chinese Participant must be first-or second-generation Han Chinese of full Chinese parentage. First-generation participants will have been born in China to two participants and four grandparents also born in China of full Chinese descent. Second-generation participants born outside of China must have two parents and four grandparents born in China of full Chinese descent. Participants must maintain a typical Chinese lifestyle, including consuming a typical Chinese diet. OR * Japanese Participant must be first-or second-generation Japanese of full Japanese parentage. First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent. Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent. All participants must maintain a typical Japanese lifestyle, including consuming a typical Japanese diet. Exclusion Criteria: * Part 1 (Groups 1-4), Part 2 and Part 3: History of any clinically significant neurological, respiratory (except mild asthma as a child), endocrine, metabolic, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness. * History of suicidal ideation within one year prior to study drug administration as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS) completed at Screening, or any history of suicide attempts within the last two years.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Acpru /Id# 270552
Grayslake, Illinois, 60030, United States
-
CenExel ACT- Anaheim Clinical Trials /ID# 276423
Anaheim, California, 92801, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental brain drug TAK-935 put to the test in healthy volunteers
- Tracing a Low-THC cannabis extract through the human body
- Can a new injection SGB-9768 pass its first safety test?
- Can a new PET tracer reveal the Body's hidden stress?
- Zapping the brain to shift Decision-Making in depression and aging
- Can a new formula make omega-3 and vitamin D3 supplements work better?